Sarcoidosis

Researchers are investigating acute myocardial inflammation, a complex condition that includes acute cellular cardiac allograft rejection ACR, cardiac sarcoidosis CS, and immune checkpoint inhibitor induced myocarditis ICIM. This study aims to evaluate the accuracy of 68GaGa-PentixaFor PETCT imaging for detecting inflammatory cells in these patients, offering a potentially non-invasive diagnostic option. The study is a phase 2 trial focusing on these specific heart inflammation conditions where diagnosis is currently challenging. Participants will receive an intravenous injection of a maximum of 50 micrograms of PentixaFor labeled with 150 15 MBq of Gallium-68 68Ga as a bolus 60 15 minutes before undergoing PETCT imaging. The treatment involves this imaging procedure for all three patient groups ACR, CS, ICIM to assess the presence and characteristics of myocardial inflammation. During the study, researchers will evaluate imaging results by analyzing lesion number, location, and standardized uptake value SUV over one year. They will also monitor toxicity data for safety assessment. Participants will have regular clinical follow-ups at the cardiology department. The study involves signing informed consent and includes monitoring for any adverse effects related to the imaging agent or procedures throughout the study duration.

Coughing is a common and distressing symptom for people with interstitial lung disease ILD, affecting daily activities, work, and social life. This research explores a non-drug cough control therapy combined with pulmonary rehabilitation to see if it is practical and helps reduce chronic cough lasting more than eight weeks in ILD patients. The study aims to assess how well patients accept this therapy and whether it improves quality of life, cough symptoms, and fatigue compared to standard pulmonary rehabilitation alone. Participants will join a pulmonary rehabilitation program involving aerobic and strengthening exercises, disease-specific education, and self-management as usual care. Two weeks before finishing this program, they will receive four virtual sessions of 45 to 60 minutes each, focusing on cough control education and techniques. These sessions include assessing cough, learning suppression methods, breathing retraining, and reinforcing strategies to manage cough in daily life. During the study, researchers will track enrollment and attendance to measure feasibility, along with various clinical outcomes like cough severity questionnaires, fatigue scales, breathlessness ratings, and patient satisfaction interviews. The intervention is delivered online via Zoom, allowing remote participation. The total study duration averages one year, with ongoing assessments to understand the therapys impact and participants experiences.

Researchers are evaluating the combination of Adebrelimab with carboplatin or cisplatin plus etoposide chemotherapy and concurrent radiotherapy as a first treatment for patients with extensive-stage oligometastatic small cell lung cancer. This Phase II open-label study aims to assess the safety and effectiveness of this regimen in this patient group. The trial is led by Nanfang Hospital, Southern Medical University and focuses on patients with limited metastatic lesions and organs affected. Participants will first receive Adebrelimab intravenously along with carboplatin or cisplatin and etoposide for two cycles during the induction phase. Next, participants undergo concurrent chemoradiotherapy, including thoracic radiation and stereotactic body radiation therapy SBRT to metastases, combined with one to two cycles of chemotherapy. Following this, they will receive one to two additional cycles of Adebrelimab combined with chemotherapy, and then continue on Adebrelimab alone as maintenance therapy until disease progression, unacceptable side effects, or withdrawal from the study. During the study, participants will be closely monitored through clinical assessments, imaging, and laboratory tests to track progression-free survival and other measures such as overall survival and response rates, with follow-up lasting up to approximately 30 months. Safety will be monitored by recording adverse events throughout the treatment and maintenance phases. The total participation time includes induction, concurrent chemoradiotherapy, maintenance, and follow-up periods to fully evaluate treatment outcomes and tolerability.

Researchers are evaluating the safety and tolerability of inhaled mosliciguat combined with inhaled treprostinil in adults with pulmonary hypertension associated with interstitial lung disease PH-ILD. This Phase 2, open-label, multi-center study focuses on participants who already use inhaled treprostinil to manage their condition. The trial aims to gather important safety information about this combination treatment in this specific lung disease population. Participants will receive daily inhaled mosliciguat during a 16-week open-label treatment period. After this period, those who complete the initial phase may continue to receive mosliciguat in an extension phase lasting beyond 16 weeks. Mosliciguat will be delivered using a dry powder inhaler device, and doses may vary among three different levels. All participants will continue treatment with inhaled mosliciguat during the extension. Throughout the study, researchers will monitor participants for treatment-emergent adverse events, serious adverse events, and any side effects leading to discontinuation, with assessments at baseline and at week 16. Participants must be able to perform a six-minute walk of at least 100 meters. The study includes imaging confirmation of interstitial lung disease and right heart catheterization to confirm pulmonary hypertension. The total participation duration may extend beyond 16 weeks depending on continuation in the extension phase.

Researchers are studying the natural progression of Interstitial Lung Disease ILD and related conditions such as Idiopathic Pulmonary Fibrosis, Sarcoidosis, and Connective Tissue Disorder. The goal is to collect detailed data and blood samples from patients receiving care in the ILD program as well as from a control group to better understand the different ways these diseases can appear and progress over time. Participants in this observational study will not receive a specific treatment but will contribute data and blood samples over time. This approach allows researchers to compare disease characteristics in affected patients with those in healthy controls, aiming to describe the phenotypic expression of these lung diseases. Throughout the study, participants will have yearly evaluations to track the natural history of their lung disease. Data collection will include clinical assessments and blood samples to monitor disease progression. The study is ongoing, with participation potentially lasting for many years, allowing for long-term observation of the disease course.

This research aims to assess the drug XTMAB-16 in adults with pulmonary sarcoidosis, a condition involving lung inflammation. The study is a combined Phase 1b2 trial focusing on patients diagnosed at least six months prior, including those with or without additional organ involvement. It follows guidelines from leading respiratory societies and seeks to understand the drugs safety and effects while tapering corticosteroid use. Participants receive XTMAB-16 or a placebo through infusions at varying doses and schedules over two parts. In Part A, patients get doses every 2 or 4 weeks for 12 weeks, with four different dosing regimens including placebo. Part B continues treatment with the dose established in Part A for 24 weeks or placebo. Participants are asked to follow certain dietary restrictions and testing requirements during the study. Throughout the study, participants undergo monitoring for adverse events and steroid dose reductions, with evaluations lasting up to 34 weeks. Assessments include safety checks, lung function tests, and tracking corticosteroid use. The study measures include the rate of side effects, ability to reduce steroid doses, and maintenance of steroid reduction. Participants provide informed consent and receive ongoing support to comply with study procedures.

Researchers are conducting an observational prospective study to build a large-scale multiomic database of adult patients undergoing advanced imaging studies. The study focuses on using recently introduced photon counting CT scanners and high-field 3T MRI scanners to explore latent imaging information, called opportunist features, which may provide new insights into disease risk and progression. This research aims to improve understanding of pathological mechanisms and enhance diagnostic and prognostic accuracy in fields such as oncology, neurology, pulmonary, and cardiovascular diseases. The study enrolls consecutive adults undergoing advanced imaging examinations at a single center using the Photon Counting CT scanner Neaotom Alpha, Siemens and 3T MRI MR 7700, Philips. Imaging raw data along with conventional images will be stored. Clinical, demographic, and laboratory information, including genetic test results when available, will be collected at enrollment. Blood samples for lab analysis will be taken during contrast media administration when applicable. Annual updates through clinical visits, telehealth, or phone interviews will be conducted to gather follow-up clinical, lab, and imaging data over a 10-year period. Participants will be asked to provide informed consent and undergo routine imaging and clinical assessments as part of their standard care. Data collection includes questionnaires, interviews, and automatic record updates when examinations occur at the study site. Researchers will monitor the development of imaging signatures linked to disease prevention, diagnosis, and treatment. The primary outcome is the creation of a comprehensive multiomics archive to support broad scientific research, with yearly follow-ups for up to 10 years.

Researchers are conducting the American Lung Association ALA Lung Health Cohort, a multi-center, long-term observational study focusing on young adults aged 25 to 35 without severe lung disease. The study aims to understand lung health by examining various factors such as environmental exposures, physical activity, biomarkers, and respiratory cell activity to identify early markers and targets to prevent chronic lung diseases. Participants will undergo an initial baseline assessment to measure lung function, including pre-bronchodilator forced expiratory volume in one second FEV1 and forced vital capacity FVC. After this, regular remote contacts through text, email, mail, or phone will be used to follow up with participants for up to 4.5 years. Pending additional funding, the study may be extended beyond 5 years to explore long-term changes in lung health. During the study, participants will provide contact information and undergo lung function tests. Follow-up data will be collected remotely to monitor lung health over time. Researchers will track lung function measures and gather information on environmental and lifestyle factors. Safety and participant status will be monitored regularly, with the total study duration potentially extending beyond 5 years depending on funding.

Researchers are investigating treatments for Mycobacterium xenopi MX lung disease, which is challenging to treat and affects many patients with chronic lung conditions or weakened immune systems. Treatment typically lasts around 18 months, based on sputum conversion, but outcomes remain poor. MX is rare in the USA but more common in France. Amikacin, an antibiotic, showed promise in animal models but was previously limited due to toxicity when given intravenously. A new form, amikacin liposome inhalation suspension ARIKAYCE4, delivers the drug via inhalation, targeting lung cells and reducing systemic exposure. ARIKAYCE4 has already been tested in lung infections caused by related bacteria.

Granulomatous lobular mastitis GLM is a rare benign breast condition that is challenging to differentiate from breast cancer through clinical exams and imaging. The cause of GLM is not well understood but may involve autoimmune issues, hormone imbalances, or infections. This condition has been increasing in certain regions, especially Mediterranean and Asian countries, and it can cause lasting physical and emotional effects due to its long course and tendency to recur. This research compares three treatment methods to find better options for patients. The study evaluates three treatments surgery alone, triple anti-tuberculosis drug therapy alone, and a combination of surgery followed by drug therapy. Surgical treatment involves removing inflamed breast tissue and damaged skin under anesthesia. The drug therapy includes oral rifampin, isoniazid, and ethambutol at specified doses. Patients receive one of these treatments, and their outcomes are compared to assess cure rates, recurrence, side effects, satisfaction, and treatment duration. Participants are women aged 15 to 65 with confirmed GLM and normal liver and kidney function. Researchers monitor differences in cure and recurrence rates, adverse reactions, patient satisfaction, and treatment length. The study collects clinical and demographic data and monitors patients throughout the treatment process. The goal is to improve understanding of treatment effectiveness and patient experiences while ensuring safety and thorough evaluation until the study ends in October 2024.